More recently, Kagamu et al. demonstrated that a high level of functional systemic CD4+ T cells before anti-PD-1 therapy correlates with PD1+ CD8+ T cells in patients with NSCLC [164]. Here, CD4 is linked to non-small cell lung carcinoma.